Centrum Silver Linked to Slowed Biological Aging in COSMOS Trial
Event summary
- A Nature Medicine study found Centrum Silver slowed biological aging markers in older adults over two years.
- Participants taking the multivitamin showed a ~4-month reduction in epigenetic aging clocks vs. placebo.
- Effects were stronger among those with accelerated baseline aging, suggesting targeted benefits.
- The COSMOS trial involved nearly 1,000 participants aged ≥60/≥65 and five DNA-based epigenetic clocks.
The big picture
This study positions Centrum Silver as a potential leader in preventative aging nutrition, an emerging category within consumer health. With Haleon's portfolio spanning six major health categories, the finding could bolster its wellness segment amid growing demand for science-backed longevity products. The trial's rigorous design—randomized, placebo-controlled, and published in Nature Medicine—lends credibility to claims that have historically lacked robust clinical backing.
What we're watching
- Clinical Validation
- Whether Haleon can leverage this data to differentiate Centrum Silver in a crowded supplement market.
- Regulatory Scrutiny
- How FDA may respond to aging-related claims given the study's observational nature.
- Commercialization Pace
- The speed at which Haleon integrates these findings into marketing and product development.
Our editorial coverage: